3 Relapsed and refractory CLL
3.1 ReVenG study
- Venetoclax plus Obinutuzumab in pts with R/R CLL
3.2 REVEAL study
- VEN plus Acalabrutinib
after Relapseon VEN plus Anti-CD20 mAb
3.3 BRUIN CLL-321 study
- Pirobrutinib vs Idelalisib-R or BR
3.4 BTK Degraders
3.4.1 BGB-16673
- Phase 1 CaDAnCe-101 Study
- n=66 patients